VF
HRTX icon

Virtu Financial’s Heron Therapeutics HRTX Stock Holding History

Virtu Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
+283,239
New +$227K ﹤0.01% 1071
2025
Q4 		– Sell
-16,928
Closed -$21K – 1896
2025
Q3 		$21K Sell
16,928
-22,665
-57% -$35.9K ﹤0.01% 1271
2025
Q2 		$82K Buy
+39,593
New +$80.9K ﹤0.01% 1062
2024
Q3 		– Sell
-40,165
Closed -$141K – 1583
2024
Q2 		$141K Buy
+40,165
New +$123K 0.01% 782
2024
Q1 		– Sell
-41,237
Closed -$70K – 1694
2023
Q4 		$70K Buy
41,237
+25,608
+164% +$28.2K 0.01% 1112
2023
Q3 		$16K Buy
+15,629
New +$22.2K ﹤0.01% 1043
2022
Q3 		– Sell
-67,900
Closed -$189K – 1923
2022
Q2 		$189K Buy
67,900
+24,331
+56% +$97.7K 0.02% 772
2022
Q1 		$249K Buy
43,569
+25,263
+138% +$185K 0.02% 671
2021
Q4 		$167K Buy
+18,306
New +$187K 0.02% 905
2021
Q1 		– Sell
-20,667
Closed -$437K – 1787
2020
Q4 		$437K Buy
+20,667
New +$359K 0.05% 478
2020
Q3 		– Sell
-39,131
Closed -$576K – 1268
2020
Q2 		$576K Buy
+39,131
New +$643K 0.07% 332
2019
Q4 		$410K Buy
+17,460
New +$386K 0.04% 508
2018
Q4 		– Sell
-27,454
Closed -$869K – 1731
2018
Q3 		$869K Buy
27,454
+17,873
+187% +$666K 0.05% 382
2018
Q2 		$372K Buy
9,581
+7
+0.1% +$223 0.02% 996
2018
Q1 		$264K Sell
9,574
-43,515
-82% -$987K 0.01% 1149
2017
Q4 		$961K Buy
53,089
+21,495
+68% +$351K 0.05% 453
2017
Q3 		$510K Buy
+31,594
New +$496K 0.03% 918

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Virtu Financial's HRTX Position: Q2 2026 in Review

Virtu Financial opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 283,239 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #1071 among its holdings. This is a return to the name: Virtu Financial previously reported a position in HRTX as recently as Q3 2025.

Virtu Financial first reported a position in HRTX in Q3 2017 and has held it in 17 quarters since. The position peaked at $961K in Q4 2017. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Virtu Financial held 283,239 shares of Heron Therapeutics worth $121K as of Q2 2026.
  • Heron Therapeutics was a new Virtu Financial position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1071 holding.
  • Virtu Financial first reported a position in Heron Therapeutics in Q3 2017 and has held it in 17 quarters since.
  • Virtu Financial's Heron Therapeutics position peaked at $961K in Q4 2017.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.